[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE8205892D0 - Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin - Google Patents

Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Info

Publication number
SE8205892D0
SE8205892D0 SE8205892A SE8205892A SE8205892D0 SE 8205892 D0 SE8205892 D0 SE 8205892D0 SE 8205892 A SE8205892 A SE 8205892A SE 8205892 A SE8205892 A SE 8205892A SE 8205892 D0 SE8205892 D0 SE 8205892D0
Authority
SE
Sweden
Prior art keywords
peptides
complex
proteins
relates
solubilizing agents
Prior art date
Application number
SE8205892A
Other languages
English (en)
Inventor
Bror Morein
Original Assignee
Bror Morein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of SE8205892D0 publication Critical patent/SE8205892D0/sv
Priority to SE8205892A priority Critical patent/SE8205892D0/sv
Application filed by Bror Morein filed Critical Bror Morein
Priority to NZ205925A priority patent/NZ205925A/en
Priority to AU20103/83A priority patent/AU558258B2/en
Priority to IE2394/83A priority patent/IE57025B1/en
Priority to ZA837603A priority patent/ZA837603B/xx
Priority to DE198383850273T priority patent/DE109942T1/de
Priority to EP83850273A priority patent/EP0109942B1/en
Priority to AT83850273T priority patent/ATE61228T1/de
Priority to DE8383850273T priority patent/DE3382190D1/de
Priority to FI833748A priority patent/FI80600C/sv
Priority to NO833769A priority patent/NO163668C/no
Priority to DK478383A priority patent/DK162057C/da
Priority to ES526524A priority patent/ES8503951A1/es
Priority to PT77515A priority patent/PT77515B/pt
Priority to CA000439130A priority patent/CA1243954A/en
Priority to AR83294560A priority patent/AR243080A1/es
Priority to US06/543,032 priority patent/US4578269A/en
Priority to MX8310844U priority patent/MX7563E/es
Priority to JP58195132A priority patent/JPH07112983B2/ja
Priority to US06/825,778 priority patent/US4744983A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SE8205892A 1982-10-18 1982-10-18 Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin SE8205892D0 (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE8205892A SE8205892D0 (sv) 1982-10-18 1982-10-18 Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
NZ205925A NZ205925A (en) 1982-10-18 1983-10-11 Immunogenic complex containing antigenic peptides and proteins with hydrophobic regions and a glycoside
AU20103/83A AU558258B2 (en) 1982-10-18 1983-10-12 Immunogenic protein complex
IE2394/83A IE57025B1 (en) 1982-10-18 1983-10-12 Immunogenic protein or peptide complex,method of producing said complex and the use thereof as an immune stimulant and as a vaccine
ZA837603A ZA837603B (en) 1982-10-18 1983-10-12 Immunogenic protein or peptide complex,method of producing said complex and the use thereof as an immune stimulant and as a vaccine
DE198383850273T DE109942T1 (de) 1982-10-18 1983-10-13 Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
EP83850273A EP0109942B1 (en) 1982-10-18 1983-10-13 Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
AT83850273T ATE61228T1 (de) 1982-10-18 1983-10-13 Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE8383850273T DE3382190D1 (de) 1982-10-18 1983-10-13 Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
FI833748A FI80600C (sv) 1982-10-18 1983-10-14 Förfarande för framställning av immunogent protein- eller peptidkomple x
CA000439130A CA1243954A (en) 1982-10-18 1983-10-17 Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
NO833769A NO163668C (no) 1982-10-18 1983-10-17 Fremgangsmaate for fremstilling av immunogent kompleks.
DK478383A DK162057C (da) 1982-10-18 1983-10-17 Fremgangsmaade til fremstilling af et immunogent kompleks
ES526524A ES8503951A1 (es) 1982-10-18 1983-10-17 Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
PT77515A PT77515B (en) 1982-10-18 1983-10-17 Immunogenic protein or peptide complex method of producing said complex and use thereof as an immune stimulant and as a vaccine
AR83294560A AR243080A1 (es) 1982-10-18 1983-10-18 Procedimiento para obtener un complejo inmunogenico entre proteinas antigenicas o peptidos con regiones hidrofobas y bisdesmosidos con regiones hidrofobas.
US06/543,032 US4578269A (en) 1982-10-18 1983-10-18 Immunogenic protein or peptide complex, method or producing said complex and the use thereof as an immune stimulant and as a vaccine
MX8310844U MX7563E (es) 1982-10-18 1983-10-18 Procedimiento para preparar un complejo inmunogeno que contiene proteinas antigenicas y peptidos
JP58195132A JPH07112983B2 (ja) 1982-10-18 1983-10-18 免疫原性複合物
US06/825,778 US4744983A (en) 1982-10-18 1986-01-31 Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8205892A SE8205892D0 (sv) 1982-10-18 1982-10-18 Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Publications (1)

Publication Number Publication Date
SE8205892D0 true SE8205892D0 (sv) 1982-10-18

Family

ID=20348235

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8205892A SE8205892D0 (sv) 1982-10-18 1982-10-18 Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Country Status (18)

Country Link
US (2) US4578269A (sv)
EP (1) EP0109942B1 (sv)
JP (1) JPH07112983B2 (sv)
AR (1) AR243080A1 (sv)
AT (1) ATE61228T1 (sv)
AU (1) AU558258B2 (sv)
CA (1) CA1243954A (sv)
DE (2) DE3382190D1 (sv)
DK (1) DK162057C (sv)
ES (1) ES8503951A1 (sv)
FI (1) FI80600C (sv)
IE (1) IE57025B1 (sv)
MX (1) MX7563E (sv)
NO (1) NO163668C (sv)
NZ (1) NZ205925A (sv)
PT (1) PT77515B (sv)
SE (1) SE8205892D0 (sv)
ZA (1) ZA837603B (sv)

Families Citing this family (297)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804624A (en) * 1982-05-21 1989-02-14 The University Of Tennessee Research Corporation Passive agglutination assay for pseudorabies antibody
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
SE8402861L (sv) * 1984-05-28 1985-11-29 Stefan Svenson Rening av biologiskt material
NL8403195A (nl) * 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
ZA872203B (en) * 1986-04-28 1988-02-24 New York Blood Center Inc Complex immunogen containing synthetic peptides
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
JP2817883B2 (ja) * 1987-12-04 1998-10-30 ザ リポソーム カンパニー，インコーポレイテッド 高度に完全なリポソームおよびその製剤法と用途
AU3048689A (en) * 1988-01-13 1989-08-11 University Of North Carolina At Chapel Hill, The Immunogenic peptides
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
US5885589A (en) * 1988-04-12 1999-03-23 Intervet International B.V. Pasteurella vaccine
DK199588D0 (da) * 1988-04-12 1988-04-12 Nordisk Droge & Kemikalie Vaccine
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
JPH03500659A (ja) * 1988-05-04 1991-02-14 ダナ‐ファーバー・キャンサー・インスチチュート・インコーポレーテッド タンパク質ミセル
US6291228B1 (en) 1988-08-03 2001-09-18 Vericore Limited Vaccine
GB8818415D0 (en) * 1988-08-03 1988-09-07 Animal Health Inst Vaccine
JPH0292996A (ja) * 1988-09-30 1990-04-03 Bror Morein アジュバントおよび脂質を含む複合体
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
CA2065414C (en) * 1989-09-15 2007-05-15 Tse-Wen Chang Treatment of autoimmune disease
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
DE4220653A1 (de) * 1992-06-26 1994-01-13 Boehringer Mannheim Gmbh Verfahren und Mittel zum Nachweis eines Analyten enthaltend glykosidische Tenside
EP0604727A1 (en) * 1992-12-31 1994-07-06 American Cyanamid Company Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
ATE236252T1 (de) * 1993-09-03 2003-04-15 Univ Mcgill Differentiell exprimierte leishmania gene und proteinen
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU4369596A (en) * 1994-11-21 1996-06-17 Virginia L. Scofield Sperm as vaccine vectors
ATE355363T1 (de) * 1995-01-27 2006-03-15 Genencor Int Verfahren zur extraktion von enzymen unter verwendung von tensiden
DE69520509T2 (de) 1995-06-07 2001-07-12 Pfizer Inc., New York In ovo impfung gegen coccidiose
MX9709870A (es) * 1995-06-07 1998-03-31 Pfizer Uso de esporocistos u occistos para preparar una vacuna contra coccidiosis.
ZA97452B (en) 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
GB9618119D0 (en) 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
ZA9710606B (en) * 1996-12-05 1998-06-12 Akzo Nobel Nv Non-virulent Mycoplasma synoviae vaccine thereof.
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6627205B2 (en) 1997-12-01 2003-09-30 Pfizer Incorporated Ovo vaccination against coccidiosis
US6495140B1 (en) 1998-01-12 2002-12-17 Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Process for the isolation, recovery and purification of non-polar extractives
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
US6984378B1 (en) 1999-02-26 2006-01-10 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
EP1171577A2 (en) 1999-04-09 2002-01-16 PHARMACIA & UPJOHN COMPANY Anti-bacterial vaccine compositions
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
BRPI0010612B8 (pt) 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vacinas
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
EP1878424A3 (en) * 1999-09-24 2008-04-09 GlaxoSmithKline Biologicals S.A. Novel vaccine
NZ518999A (en) * 1999-11-19 2002-12-20 Csl Ltd Vaccine compositions
CA2402252A1 (en) 2000-03-17 2001-09-27 Pharmacia & Upjohn Company Salmonella vaccine materials and methods
AU2001251370A1 (en) 2000-04-06 2001-10-23 Pharmacia And Upjohn Company Antimicrobial methods and materials
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
EP1326638B9 (en) * 2000-10-18 2008-02-20 GlaxoSmithKline Biologicals S.A. Vaccines against cancers
US20050019340A1 (en) * 2000-10-18 2005-01-27 Nathalie Garcon Vaccines
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
EP1377320B1 (en) 2001-04-04 2008-10-01 Nordic Vaccine Technology A/S Polynucleotide binding complexes comprising sterols and saponins
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2003020917A1 (en) 2001-08-30 2003-03-13 Embrex, Inc. Improved methods for producing oocysts
US20140248273A1 (en) 2001-09-08 2014-09-04 Jos van Strijp Vaccine based on staphylococcal superantigen-like 3 protein (ssl3)
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CA2494197C (en) 2002-08-12 2012-10-09 Akzo Nobel N.V. Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
US7125425B2 (en) * 2002-10-21 2006-10-24 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
DE60335742D1 (de) 2002-11-20 2011-02-24 Bestewil Holding Bv Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
PT2191844E (pt) 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (en) 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
EP1740217B1 (en) 2004-04-30 2011-06-15 Novartis Vaccines and Diagnostics S.r.l. Meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
JP2008500984A (ja) 2004-05-28 2008-01-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヴィロソームとサポニンアジュバントを含むワクチン組成物
NZ553244A (en) 2004-07-18 2009-10-30 Csl Ltd Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
BRPI0606481A2 (pt) 2005-01-20 2009-06-30 Isconova Ab composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectina
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
NZ561042A (en) 2005-02-18 2011-03-31 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
AU2006257383A1 (en) 2005-06-16 2006-12-21 Universiteit Gent Vaccines for immunization against Helicobacter
ES2357679T3 (es) 2005-07-28 2011-04-28 Pfizer Products Inc. VACUNA CONTRA CALICIVIRUS FELINO (FCV) QUE COMPRENDE UNA PROTEINA DE CAPSIDA DE UN FCV O UNA PROTEINA DE LA CAPSIDA DE UN FCV AISLADA QUE COMPRENDE UNA SECUENCIA PROTEICA SEC ID Nº: 13 O SECUENCIAS PROTEICAS CON, AL MENOS, 95% DE IDENTIDAD CON ELLA.
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
CN101309701A (zh) 2005-10-07 2008-11-19 辉瑞产品公司 治疗犬流感的疫苗和方法
CN101355960A (zh) 2005-10-18 2009-01-28 诺华疫苗和诊断公司 使用α病毒复制子颗粒进行粘膜和全身免疫
PT2368572T (pt) 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
EP1969001A2 (en) 2005-11-22 2008-09-17 Novartis Vaccines and Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SI1962899T1 (sl) 2005-12-22 2011-11-30 Glaxosmithkline Biolog Sa Pnevmokokna polisaharidna konjugatna vakcina
PT2478916T (pt) 2006-01-27 2020-07-03 Seqirus Uk Ltd Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
EP2476434A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
AU2007263531B2 (en) 2006-06-29 2012-03-15 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
KR20090094213A (ko) 2006-07-18 2009-09-04 글락소스미스클라인 바이오로지칼즈 에스.에이. 말라리아 백신
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2484375T3 (en) 2006-09-26 2018-07-16 Infectious Disease Res Inst Vaccine composition comprising synthetic adjuvant
ES2480491T3 (es) 2006-12-06 2014-07-28 Novartis Ag Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
EP2762163B1 (en) 2006-12-27 2018-01-03 Zoetis Services LLC Methods of vaccine administration
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2688284A1 (en) 2007-05-25 2008-12-04 Novartis Ag Streptococcus pneumoniae pilus antigens
CN101784282B (zh) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2561483T3 (es) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa Antígenos mutantes de GAS57 y anticuerpos de GAS57
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US10040825B2 (en) 2007-12-19 2018-08-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
BRPI0821240B8 (pt) 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
HUE029258T2 (en) 2007-12-24 2017-02-28 Id Biomedical Corp Quebec Recombinant RSV antigens
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
US20110014230A1 (en) 2008-03-18 2011-01-20 Novartis Ag preparation of influenza virus vaccine antigens
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
PE20151588A1 (es) 2009-02-17 2015-11-18 Glaxosmithkline Biolog Sa Vacuna contra el virus del dengue
AU2010220103A1 (en) 2009-03-06 2011-09-22 Novartis Ag Chlamydia antigens
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
CN109248313B (zh) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
WO2010146414A1 (en) 2009-06-15 2010-12-23 National University Of Singapore Influenza vaccine, composition, and methods of use
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
CA2766205A1 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
WO2011005183A1 (en) * 2009-07-10 2011-01-13 Isconova Ab New composition
PT3178490T (pt) 2009-07-15 2022-06-30 Glaxosmithkline Biologicals Sa Composições de proteína f de rsv e métodos para produção das mesmas
EP2837386B1 (en) 2009-07-16 2018-03-07 GlaxoSmithKline Biologicals SA Detoxified Escherichia coli immunogens
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
JP2013504556A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
MX338753B (es) 2009-09-30 2016-04-29 Novartis Ag Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
BR112012009309B1 (pt) 2009-10-19 2021-10-05 Intervet International B.V Vacina combinada, uso de células de microrganismos,método para a preparação de uma vacina combinada, e, kit de partes
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
EP2490716A1 (en) 2009-10-22 2012-08-29 Universität Leipzig Detection of a circovirus in calves suffering from bovine neonatal pancytopenia
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
WO2011117408A1 (en) 2010-03-26 2011-09-29 Glaxosmithkline Biologicals S.A. Hiv vaccine
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011130379A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
EP2560985B1 (en) 2010-04-21 2016-06-29 Pharmaq AS Nucleic acid sequences of a fish virus and the use thereof
US8623376B2 (en) 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
PL2585045T3 (pl) 2010-06-24 2020-01-31 F.Hoffmann-La Roche Ag Kompozycje i sposoby zawierające alkiloglikozydy do stabilizacji formulacji zawierających białka
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
CN103052401A (zh) 2010-07-23 2013-04-17 伊斯克诺瓦公司 流感疫苗
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
KR20130139953A (ko) 2010-09-27 2013-12-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012059593A1 (en) 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
EP2640832B1 (en) 2010-11-15 2017-12-20 Pharmaq AS New ethiological agent
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
JP2014500267A (ja) 2010-12-08 2014-01-09 ネオヴァクス 強力に不活性化されているがなお高い免疫原性を示すワクチンおよびその製造方法
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
US20130287786A1 (en) 2010-12-29 2013-10-31 Theodorus Petrus Maria Schetters Canine babesiosis vaccine antigen
CA2822115C (en) 2010-12-29 2022-05-24 Intervet International B.V. Salmonid alphavirus protein e2
JP6077858B2 (ja) * 2011-01-07 2017-02-08 東亞合成株式会社 抗疎水性ペプチド抗体を得るための抗原調製方法
LT2667892T (lt) 2011-01-26 2019-05-10 Glaxosmithkline Biologicals Sa Rsv imunizacijos režimas
US20140086954A1 (en) 2011-03-31 2014-03-27 Chu De Toulouse Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
MX348380B (es) 2011-04-07 2017-06-09 Neovacs Pruducto inmunogénico para usarse en vacunas.
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
EP3251692B1 (en) 2011-05-13 2023-09-27 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
AU2012319239B2 (en) 2011-10-03 2017-04-20 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
ES2812564T3 (es) 2011-11-23 2021-03-17 Bioven 3 Ltd Proteínas recombinantes y sus usos terapéuticos
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
EP3563834A1 (en) 2012-02-07 2019-11-06 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
JP2015518845A (ja) 2012-05-22 2015-07-06 ノバルティス アーゲー 髄膜炎菌血清群ｘコンジュゲート
JP6066222B2 (ja) 2012-05-28 2017-01-25 東亞合成株式会社 抗菌ペプチド及びその利用
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
WO2014018274A1 (en) 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
SG11201500978TA (en) 2012-10-03 2015-07-30 Glaxosmithkline Biolog Sa Immunogenic compositions
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
WO2014083060A2 (en) 2012-11-30 2014-06-05 Novartis Ag Pseudomonas antigens and antigen combinations
LT2970398T (lt) 2013-03-13 2024-08-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv f baltymai prieš susiliejimą ir jų naudojimas
EP2970409A2 (en) 2013-03-15 2016-01-20 Bioven 3 Limited Self-assembling synthetic proteins
WO2014140166A2 (en) 2013-03-15 2014-09-18 Glaxosmithkline Biologicals S.A. Vaccine
EP2978448B1 (en) 2013-03-26 2018-05-30 The Pirbright Institute Stabilised fmdv capsids
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN105555304A (zh) 2013-08-05 2016-05-04 葛兰素史密丝克莱恩生物有限公司 联合免疫原性组合物
CA2926984A1 (en) 2013-10-11 2015-04-16 Servicio Galego de Saude (Sergas) Live attenuated vaccines
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
AU2014366281A1 (en) 2013-12-16 2016-05-26 Zoetis Services Llc Hendra and Nipah virus G glycoprotein immunogenic compositions
PT3089754T (pt) 2013-12-31 2021-07-23 Infectious Disease Res Inst Formulações de vacina de dose única
HUE047808T2 (hu) 2014-03-26 2020-05-28 Glaxosmithkline Biologicals Sa Mutáns Staphylococcus antigének
US10813984B2 (en) 2014-04-24 2020-10-27 Rhode Island Hospital Aspartate-β-hydroxylase induces epitope-specific T cell responses in tumors
WO2015189425A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
EP3172324A4 (en) 2014-07-18 2018-04-25 Oregon Health & Science University 5'-triphosphate oligoribonucleotides
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
CN104250640A (zh) 2014-08-22 2014-12-31 普莱柯生物工程股份有限公司 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
ES2788393T3 (es) 2014-09-03 2020-10-21 Intervet Int Bv Coronavirus de bovino atenuado y vacunas relacionadas
WO2016050961A1 (en) 2014-10-03 2016-04-07 Intervet International B.V. Broad-spectrum vaccine against avian reovirus
CN107001449A (zh) 2014-10-15 2017-08-01 芝诺锡拉公司 具有降低的免疫原性的组合物
US10813993B2 (en) 2015-03-03 2020-10-27 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
CN111560355A (zh) 2015-03-20 2020-08-21 普莱柯生物工程股份有限公司 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用
WO2016201224A1 (en) 2015-06-10 2016-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Processes for production and purification of nucleic acid-containing compositions
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
CN105770887A (zh) * 2016-03-04 2016-07-20 邓招红 一种用于hbv疫苗的佐剂及其制备方法
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
WO2018035199A1 (en) 2016-08-17 2018-02-22 Pharmaq As Sea lice vaccine
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
MX2019006349A (es) 2016-12-16 2019-08-22 Inst Res Biomedicine Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
WO2019016597A2 (en) 2017-07-18 2019-01-24 Bioven 3 Limited SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
KR20210004959A (ko) 2018-03-19 2021-01-13 노바백스, 인코포레이티드 다가 인플루엔자 나노입자 백신
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
CN112912097A (zh) 2018-08-23 2021-06-04 葛兰素史密丝克莱恩生物有限公司 免疫原性蛋白和组合物
JP2022532944A (ja) 2019-05-25 2022-07-20 アクセス ツー アドバンスト ヘルス インスティチュート アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法
JP2022539067A (ja) 2019-06-25 2022-09-07 イン３バイオ・リミテッド 安定化キメラ合成タンパク質及びその治療的使用
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
KR20230117166A (ko) 2020-12-02 2023-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 공여자 가닥 보완된 FimH
US20240294612A1 (en) 2020-12-23 2024-09-05 Xenothera Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherapy
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
EP4448548A1 (en) 2021-12-13 2024-10-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Bacteriophage lambda-vaccine system
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2023225458A1 (en) 2022-05-16 2023-11-23 Zoetis Services Llc Vaccines against moritella viscosa
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4251509A (en) * 1980-01-31 1981-02-17 Wisconsin Alumni Research Foundation Dry particulate vaccine for oral administration
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
CA1206094A (en) * 1981-01-09 1986-06-17 Thomas P. Hopp Synthetic antigenic composition and process for making same
GB2093039B (en) * 1981-01-29 1984-06-06 Nat Res Dev Improvements relating to hepatitis b vaccine
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Also Published As

Publication number Publication date
NZ205925A (en) 1987-10-30
MX7563E (es) 1989-10-17
FI80600B (fi) 1990-03-30
PT77515A (en) 1983-11-01
AU558258B2 (en) 1987-01-22
FI833748A0 (fi) 1983-10-14
FI833748A (fi) 1984-04-19
DK162057B (da) 1991-09-09
JPH07112983B2 (ja) 1995-12-06
IE832394L (en) 1984-04-18
ATE61228T1 (de) 1991-03-15
EP0109942A3 (en) 1985-08-14
NO163668C (no) 1990-07-04
US4578269A (en) 1986-03-25
FI80600C (sv) 1990-07-10
NO163668B (no) 1990-03-26
EP0109942B1 (en) 1991-03-06
US4744983A (en) 1988-05-17
CA1243954A (en) 1988-11-01
DK478383A (da) 1984-04-19
DK162057C (da) 1992-02-10
ES526524A0 (es) 1985-04-01
AR243080A1 (es) 1993-07-30
EP0109942A2 (en) 1984-05-30
IE57025B1 (en) 1992-03-25
DK478383D0 (da) 1983-10-17
AU2010383A (en) 1984-05-03
ES8503951A1 (es) 1985-04-01
DE3382190D1 (de) 1991-04-11
NO833769L (no) 1984-04-24
DE109942T1 (de) 1984-12-06
JPS59186921A (ja) 1984-10-23
PT77515B (en) 1986-04-16
ZA837603B (en) 1984-12-24

Similar Documents

Publication Publication Date Title
SE8205892D0 (sv) Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ATE71303T1 (de) Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
SE8405493D0 (sv) Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE168272T1 (de) Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
ATE130198T1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
KR900002651B1 (ko) 면역성이 높은 신규한 형상의 간염 b 표면항원-함유 입자의 제조방법
Kabanov et al. Fatty acid acylated antibodies against virus suppress its reproduction in cells
Lin et al. Cell fusion induced by a virus within the zona pellucida of mouse eggs
Judge et al. Ultrastructure of Trypanosoma lewisi
Jacob et al. Structure of a bacterial photosynthetic membrane: Isolation, polypeptide composition, and selective proteolysis
Simpson et al. Cytotoxicity of the glycolipid region of streptococcal lipoteichoic acid for cultures of human heart cells
Semprevivo Exometabolites of Leishmania donovani promastigotes. I. Isolation and initial characterization
WO2013043033A2 (es) Método de extracción, comprobacíon de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferecia potencializado, específicamente diseñado para su uso como adyuvante potencializador de vacunas virales
DK302987A (da) Fremgangsmaade til fremstilling af et immunogent kompleks
Fujimoto et al. The role of lymphoid cells in homograft rejection: circulating and cellular aspects
KR0173365B1 (ko) C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
Alaupovic et al. Relationship of Chemical Structure to Hemodynamic Properties of Endotoxins
Dalsgaard Saponin adjuvants. V. Precipitation of serum components by non-purified saponin adjuvants in agar gel diffusion.
BLYDEN PRODUCTION, PURIFICATION AND PROPERTIES OF LYMPHOCYTE ACTIVATING FACTOR.
US20050238653A1 (en) Pharmaceutical compositions containing extracted MHC molecules, for stimulation of the immune system
Kordová et al. Differentiation of hemagglutinins in tissues infected with Chlamydia
Entwistle Antibody to Vaccinia
Miller The immunologic activity of subcellular fractions and soluble protein from a murine fibrosarcoma
BR9711809A (pt) Polipeptìdeo antigênico ou imunogênico, processos para tratar ou prevenir uma doença ou distúrbio em um indivìduo provocado por infecção com htlv-i, e com htlv-ii, para elicitar em um indivìduo a produção de anticorpos que especificamente ligam-se às proteìnas envelopes htlv-ii e htlv-i, e, para gerar uma resposta imune em um indivìduo
Ristau et al. Differences of the in vitro reactivity of lymphocytes from normal and persistently lymphocytotic cows to enzootic bovine leukosis tumour membrane extracts as detected with the macrophage-electrophoretic mobility test